<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Terapevticheskii arkhiv</journal-id><journal-title-group><journal-title xml:lang="en">Terapevticheskii arkhiv</journal-title><trans-title-group xml:lang="ru"><trans-title>Терапевтический архив</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0040-3660</issn><issn publication-format="electronic">2309-5342</issn><publisher><publisher-name xml:lang="en">LLC Obyedinennaya Redaktsiya</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">33406</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Editorial article</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Передовая статья</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Transplantation of allogenic bone marrow inacute leukemias and chronic myeloid leukemia</article-title><trans-title-group xml:lang="ru"><trans-title>ТРАНСПЛАНТАЦИЯ АЛЛОГЕННОГО КОСТНОГО МОЗГА ПРИ ОСТРЫХ ЛЕЙКОЗАХИ ХРОНИЧЕСКОМ МИЕЛОЛЕЙКОЗЕ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Mendeleeva</surname><given-names>L P</given-names></name><name xml:lang="ru"><surname>Менделеева</surname><given-names>Л П</given-names></name></name-alternatives><bio xml:lang="ru"><p>ГНЦ РАМН, Москва</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">ГНЦ РАМН, Москва</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2003-07-15" publication-format="electronic"><day>15</day><month>07</month><year>2003</year></pub-date><volume>78</volume><issue>7</issue><issue-title xml:lang="en">NO7 (2003)</issue-title><issue-title xml:lang="ru">ТОМ 78, №7 (2003)</issue-title><fpage>89</fpage><lpage>94</lpage><history><date date-type="received" iso-8601-date="2020-04-13"><day>13</day><month>04</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2003, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2003, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2003</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ter-arkhiv.ru/0040-3660/article/view/33406">https://ter-arkhiv.ru/0040-3660/article/view/33406</self-uri><abstract xml:lang="en"><p/></abstract><trans-abstract xml:lang="ru"><p/></trans-abstract><kwd-group xml:lang="en"><kwd>review</kwd><kwd>transplantation of allogenic bone marrow</kwd><kwd>acute leukemias</kwd><kwd>chronic myeloid leukemia</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>обзор</kwd><kwd>трансплантация аллогенного костного мозга</kwd><kwd>острые лейкозы</kwd><kwd>хронический миелолейкоз</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Thomas E. D., Lochte H. L., Lu W. С. et al. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N. Engl. J. Med. 1957; 257: 491-496.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Fefer A., Einstein А. В., Thomas E. D. Bone-marrow transplantation for hematologic neoplasia in 16 patients with identical twins. Ibid. 1974; 290: 1389-1393.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Thomas E. D., Lochte H. L., Ferrebee J. W. Irradiation of the entire body and marrow transplantation: some observations and comments. Blood 1959; 14: 1-23.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Thomas E. D., Buckner С. D., Banaji M. et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Ibid. 1977;49:511-533.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Fefer A., Thomas E. D. Marrow transplantation in the treatment of acute leukemia. In: Henderson E. S., Lister T. A. Leukemia. Philadelphia: W. B. Saunders Company; 1990. 431-441.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Zander A. R., Keating M., Dicke K. et al. A comparison of marrow transplantation with chemotherapy for adults with acute leukemia of poor prognosis in first complete remission. J. Clin. Oncol. 1988; 6: 1548-1557.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Forman S. J., Scymidt G. M., Nademanee A. P. et al. Allogeneic bone marrow transplantation as therapy for primary induction failure for patients with acute leukemia. Ibid. 1991: 9: 1570-1574.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Любимова Л. С., Савченко В. Г., Менделеева Л. П. и др. Эффективность трансплантации аллогенного костного мозга у больных острыми лейкозами в фазе полной ремиссии и у больных хроническим миелолейкозом в хронической фазе. Тер. арх. 1999; 7: 27-32.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>McGlave P. В., Haake R. J., Bostrom В. С. et al. Allogeneic bone marrow transplantation for acute nonlymphocytic leukemia in first remission. Ibid. 1988; 72: 1512-1517.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Young J. W., Papadopoulos E. В., Cunningham I. et al. T-cell- depleted allogeneic bone marrow transplantation in adults with acute nonlymphocytic leukemia in first remission. Ibid. 1992; 79: 3380-3387.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Appelbaum F. R., Dahlberg S., Thomas E. D. et al. Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. A prospective comparison. Ann. Intern. Med. 1984; 101: 581-588.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Schiller G. L., Nimer S. D., Territo M. С. et al. Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remission. J. Clin. Oncol. 1992; 10: 41-46.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Reiffers J., Gaspard M. N., Maraninchi D. et al. Comparison of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukemia in first remission: A prospective controlled trail. Br. J. Haematol. 1989; 72: 57-63.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Mitus A. J., Miller К. В., Schenkein D. P. et al. Improved survival for patients with acute myelogenous leukemia. J. Clin. Oncol. 1995; 13: 560-569.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Gorin N. C., Labopin M., Fouillard L. et al. Retrospective evaluation of autologous bone marrow transplantation vs allogeneic bone marrow transplantation from an HLA identical related donor in acute myelocytic leukemia. A study of the European Cooperative Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 1996; 18: 111-117.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Zittoum R. A., Mandelli F., Willemze R. et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N. Engl. J. Med. 1995; 332: 217-223.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Bostrom В., Brunning R. D., McGlave P. et al. Bone marrow transplantation for acute nonlymphocytic leukemia in first remission: analysis of prognostic factors. Blood. 1985; 65:1191- 1196.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Fagioli F., Bacigalupo A., Frassoni F. et al. Allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission: the effect of FAB classification and GVHD prophilaxis. Bone Marrow Transplant. 1994; 13: 247- 252,</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Keating S., Suciu S., Witte T. et al. Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: An analysis of the EORTC/GIMEMA AML 8A trial. Ibid. 1996; 17:993-1001.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Ferrant A., Labopin M., Frassoni F. et al. Karyotype in acute myeloblasts leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation Study. Blood 1997; 90: 2931-2938.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Appelbaum F. R., Clift R. A., Buckner C. D. et al. Allogeneic marrow transplantation for acute nonlymphoblastic leukemia after first relapse. Ibid. 1983; 61: 949-953.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Gale R. P., Horowits M. M., Rees J. K. et al. Chemotherapy versus transplants for acute myelogenous leukemia in second remission. Leukemia 1996; 10: 13-19.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Sebban C., Lepage E., Vemant J. P. et al. Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: A comparative study. J. Clin. Oncol. 1994; 12: 2580-2587.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Vey N., Blaise D., Stoppa A. M. et al. Bone marrow transplantation in 63 adult patients with acute lymphoblastic leukemia in first complete remission. Bone Marrow Transplant. 1994; 14: 383-388.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Chao N. J., Forman S. J., Schmidt G. M. et al. Allogeneic bone marrow transplantation for hihg-risk acute lymphoblastic leukemia during first complete remission. Blood 1991; 78: 1923-1927.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Appelbaum F. R. Allogeneic hematopoietic stem cell transplantation for acute leukemia. Semin. Oncol. 1997; 24: 114-123.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Doney K., Fisher L. D., Appelbaum F. R. et al. Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft-versus-host disease, relapse and relapse-free survival. Bone Marrow Transplant. 1991; 7: 453-459.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Wingard J. R., Piantadosi S., Santos G. W. et al. Allogeneic bone marrow transplantation for hihg-risk acute lymphoblastic leukemia. J. Clin. Oncol. 1990; 8: 820-830.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Hehlmann R., Heimpel H., Hasford J. et al. Randomised comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: Prolongation of survival by hydroxyurea. Blood 1993; 82: 398-407.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Guilhot F., Chastang C., Michallet M. et al. Interferon alpha-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N. Engl. J. Med. 1997; 337: 223-229.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Ohnishi K., Ohno R., Tomonaga M. et al. A randomized trial comparing interferon-a with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 1995; 86: 906-916.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Hochhaus A., Kantarjian H. M., Sawyers C. L. et al. Glivek (Imatinib Mesylate, STI571) induces hematologic and cytogenetic responses in the majority of patients with chronic myeloid leukemia in late chronic phase. Hematol. J. 2001; 1 (suppi. 1 Abstracts for the 6"' Annual Meeting of the European Haematology Association): abstr. 736.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Fefer A., Cheever M. A., Thomas E. D. et al. Disappearance of Ph'-positive cells in four patients with chronic granulocytic leukemia after chemotherapy, irradiation and marrow transplantation from an identical twin. N. Engl. J. Med. 1979; 300: 333-337.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Fefer A., Cheever M. A., Greenberg P. D. et al. Treatment of chronic granulocytic leukemia with chemoradiotherapy and transplantation of marrow from identical twins. Ibid. 1982; 306: 63-68.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Thomas E. D., Clift R. A., Fefer A. et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann. Intern. Med. 1986; 104: 155-163.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Clift R. A., Appelbaum F. R., Thomas E. D. et al. Treatment of chronic myeloid leukemia by marrow transplantation. Blood 1993; 82: 1954-1956.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Cross N., Feng L., Chase A. et al. Competitive polymerase chain reaction to estimate the numbsr of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Ibid : 1929-1936.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Biggs J. C., Szer J., Crilley P. et al. Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2. Ibid. 1992; 80: 1090-1093.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Clift R. A., Buckner С. D., Thomas E. D. et al. Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia. Ibid. 1994; 84: 4368-4373.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Devergie A., Reiffers J., Vernant J. P. et al. Long-term follow-up after bone marrow transplantation for chronic myelogenous leukemia: Factors associated with relapse. Bone Marrow Transplant. 1990; 5: 379-386.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Bortin M. M., Horowitz M. M., Rimm A. A. Progress report from the International Bone Marrow Registry. Ibid. 1992; 10: 113-122.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Bauduer F., Delmer A., Blanc M. С. et al. Treatment of chronic myelogenous leukemia in blast crisis and in accelerated phase with hihg- or intermediate-dose cytosine arabinoside and amcacrine. Leukemia and Lymphoma 1993; 10: 195-200.</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Derderian P. M., Kantarjian H. M., Talpaz M. et al. Chronic myelogenous leukemia in the lymphoid blastic stage: Characteristics, treatment response and prognosis. Am. J. Med. 1993; 94: 69-74.</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Collins R., Rogers Z., Bennett M. et al. Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: Apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression. Bone Marrow Transplant. 1992; 10: 391-395.</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Kolb H-J., Schattenberg A., Goldman J. M. et al. Graft-versusleukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-2050.</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Mortimer J., Blinder M. A., Schulman S. et al. Relapse of acute leukemia after marrow transplantation: Natural history and results of subsequent therapy. J. Clin. Oncol. 1989; 7: 50-57.</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Frassoni F., Barrett A. J., Granena A. et al. Relapse after allogeneic bone marrow transplantation for acute leukemia: A survey by the EBMT of 117 cases. Br. J. Haematol. 1988; 70: 317-320.</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Chiang K. Y., Weisdorf D., Daves S. M. et al. Outcome of second bone marrow transplantation following a uniform conditioning regimen as therapy for malignant relapse. Bone Marrow Transplant. 1996; 17: 39-42.</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Lalit K. Leukemia: Management of relapse after allogeneic bone marrow transplantation. J. Clin. Oncol. 1994; 12: 1710- 1717.</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Wagner J. E., Vogelsang G. В., Zehnbauer B. A. et al. Relapse of leukemia after bone marrow transplantation: Effect of second myeloablative therapy. Bone Marrow Transplant. 1992; 9: 205-209.</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Giralt S., Escudier S., Kantarijan H. et al. Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. N.Engl. J. Med. 1993; 329: 757-761.</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Giralt S., Champlin R. E. et al. Leukemia relapse after allogeneic bone marrow transplantation. Blood 1994; 84: 3603- 3612.</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Arcese W., Goldman J. M., Darcangelo E. et al. Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Ibid. 1993; 82: 3211-3219.</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>Higano С. S., Raskind W. H., Singer J. W. et al. Use of alpha interferon for the treatment of relapse of chronic myelogenous leukemia in chronic phase after allogeneic marrow transplantation. Ibid. 1992; 80: 1437-1442.</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>Kolb H. J., Mittermueller J., Clemm С. et al. Donor leukocyte transfusions for treatment of reccurrent chronic myelogenous leukemia in marrow transplant patients. Ibid. 1990: 76: 2462- 2465.</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>Fores R., Diez-Martin J. L., Briz M et al. Donor leukocyte infusions for treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1996; 17: 439-441.</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation>Savchenko V., Mendeleeva L., Lubimova L. et al. Donor leukocyte infusion (DL1) in the treatment of AML patients relapsed after allogeneic bone marrow transplantation. (Hiddemann W. et al. Acute leukemias V. Experimental approaches and management of refractory diseases). Berlin; 1996. 383-385.</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation>Szer J., Grigg A. P., Phillips G. L. et al. Donor leukocyte infusions after chemotherapy for patients relapsing with acute leukemia following allogeneic BMT. Bone Marrow Transplant. 1993; 11: 109-111.</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation>Барретт А. Ж. Механизмы реакции трансплантат-против-лейкоза. Пробл. гематол. 1997; 4: 5-16.</mixed-citation></ref></ref-list></back></article>
